Literature DB >> 11818155

Induction of protective antiviral cytotoxic T cells by a tubular structure capable of carrying large foreign sequences.

Mrinal K Ghosh1, Edith Dériaud, Marie Françoise Saron, Richard Lo-Man, Thomas Henry, Xinan Jiao, Polly Roy, Claude Leclerc.   

Abstract

Bluetongue virus (BTV) produces large numbers of tubules during infection which are formed by a single virus coded non-structural protein, NS1. The NS1 protein has been fused with full length green fluorescent protein (GFP) and was shown to retain the capacity to form tubules when expressed in heterologous expression systems. Moreover, recombinant purified chimeric tubules were demonstrated to be internalized by macrophages and dendritic cells. The ability of such chimeric tubules to induce protective cytotoxic T lymphocytes (CTL) responses has been assessed by generating chimeric tubules carrying a single CD8(+) T cell epitope from the lymphocytic choriomeningitis virus (LCMV) nucleoprotein. These chimeric tubules were recognized by MHC class I restricted T cell hybridoma in vitro and induced in vivo strong CD8(+) class I-restricted CTL responses in immunized mice. Further, the immunized mice were protected when challenged with a lethal dose of LCMV. This is the first study that demonstrates that the virus derived tubules synthesized by a recombinant non-structural protein carrying a single viral CTL epitope could induce protective immunity against a lethal viral challenge. Since recombinant tubules carrying large inserts can be purified at a large quantity from insect cells, they have potential to develop as safe multi-CTL vaccine delivery systems.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11818155     DOI: 10.1016/s0264-410x(01)00467-4

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  9 in total

1.  A highly optimized DNA vaccine confers complete protective immunity against high-dose lethal lymphocytic choriomeningitis virus challenge.

Authors:  Devon J Shedlock; Kendra T Talbott; Christina Cress; Bernadette Ferraro; Steven Tuyishme; Karthik Mallilankaraman; Neil J Cisper; Matthew P Morrow; Stephan J Wu; Omkar U Kawalekar; Amir S Khan; Niranjan Y Sardesai; Karuppiah Muthumani; Hao Shen; David B Weiner
Journal:  Vaccine       Date:  2011-01-14       Impact factor: 3.641

2.  Induction of human immunodeficiency virus type 1-specific T cells by a bluetongue virus tubule-vectored vaccine prime-recombinant modified virus Ankara boost regimen.

Authors:  Natasha Larke; Aileen Murphy; Christoph Wirblich; Denise Teoh; Marie J Estcourt; Andrew J McMichael; Polly Roy; Tomás Hanke
Journal:  J Virol       Date:  2005-12       Impact factor: 5.103

3.  Comparative immunogenicity in mice of rotavirus VP6 tubular structures and virus-like particles.

Authors:  Suvi Lappalainen; Kirsi Tamminen; Timo Vesikari; Vesna Blazevic
Journal:  Hum Vaccin Immunother       Date:  2013-06-18       Impact factor: 3.452

4.  Rotavirus capsid VP6 protein acts as an adjuvant in vivo for norovirus virus-like particles in a combination vaccine.

Authors:  Vesna Blazevic; Maria Malm; Daisuke Arinobu; Suvi Lappalainen; Timo Vesikari
Journal:  Hum Vaccin Immunother       Date:  2016-03-03       Impact factor: 3.452

Review 5.  Nanoparticle- and Microparticle-Based Vaccines against Orbiviruses of Veterinary Importance.

Authors:  Luis Jiménez-Cabello; Sergio Utrilla-Trigo; Natalia Barreiro-Piñeiro; Tomás Pose-Boirazian; José Martínez-Costas; Alejandro Marín-López; Javier Ortego
Journal:  Vaccines (Basel)       Date:  2022-07-14

6.  Trivalent combination vaccine induces broad heterologous immune responses to norovirus and rotavirus in mice.

Authors:  Kirsi Tamminen; Suvi Lappalainen; Leena Huhti; Timo Vesikari; Vesna Blazevic
Journal:  PLoS One       Date:  2013-07-26       Impact factor: 3.240

7.  Anti Leishmanial Effect of Zinc Sulphate on the Viability of Leishmania tropica and L. major Promastigotes.

Authors:  Ali Fattahi Bafghi; Mohammad Noorbala; Mohammad Taghi Noorbala; Mahdi Aghabagheri
Journal:  Jundishapur J Microbiol       Date:  2014-09-01       Impact factor: 0.747

8.  Rotavirus Recombinant VP6 Nanotubes Act as an Immunomodulator and Delivery Vehicle for Norovirus Virus-Like Particles.

Authors:  Maria Malm; Kirsi Tamminen; Suvi Lappalainen; Timo Vesikari; Vesna Blazevic
Journal:  J Immunol Res       Date:  2016-09-04       Impact factor: 4.818

Review 9.  Virus-like particles as a vaccine delivery system: myths and facts.

Authors:  Polly Roy; Rob Noad
Journal:  Adv Exp Med Biol       Date:  2009       Impact factor: 2.622

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.